Form 4: Cyclerion Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
Peter M Hecht, a Director and 10% owner of Cyclerion Therapeutics, Inc., reported multiple transactions in common stock on July 16, 2026.
Summary
- Conversion of derivative: acquired 351,037 Common Stock on July 16, 2026; holds 910,240 after (Direct).
- Conversion of derivative: disposed of 351,037 Series A Convertible Preferred Stock on July 16, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Peter M Hecht — Director, 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-16 | Conversion of derivative | Common Stock | 351,037 | — | — | 910,240 |
| 2026-07-16 | Conversion of derivative | Series A Convertible Preferred Stock | 351,037 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-16 | Conversion of derivative (351,037 shares) |
| 2026-07-16 | Conversion of derivative (351,037 shares) |
Keywords
insider transaction, Form 4, CYCN, Cyclerion Therapeutics, Inc., neutral, Peter M Hecht
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.